Treace Medical Concepts signed an agreement to acquire certain assets of RedPoint Medical3D (RPM-3D), a medical technology company offering pre-operative planning and patient-specific guides designed to deliver surgical correction of deformities customized to the patient’s unique foot anatomy, for USD $20 million in an upfront cash payment, with up to $10 million in potential milestone payments.
Using patient CT scan data, RPM-3D applies software technologies to develop a three-dimensional pre-operative plan for correcting the patient’s deformity and produce a 3D-printed, patient-specific cut guide designed to efficiently make accurate, corrective cuts. RPM-3D software and systems will be integrated with Treace’s instrumentation and implant systems in 2023, with commercial introduction of patient-specific products expected in 2H24.
This announcement follows Treace Medical’s recently launched Adductoplasty Midfoot Correction System, SpeedRelease and TriTome Release Instruments, and S4A Anatomic Plating Kit; and its Micro-Lapiplasty Minimally Invasive System and SpeedPlate Rapid Compression Implant System, which are expected for full commercial release in late 2023.
John T. Treace, CEO, Founder and Board Member of Treace, said, “RPM-3D’s 22 patent applications further expand and reinforce our market-leading global IP portfolio covering technologies for the correction of bunion and related deformities. In addition, the RPM-3D purchase builds upon our acceleration in R&D initiatives that we announced in early 2022.”
Treace Medical Concepts signed an agreement to acquire certain assets of RedPoint Medical3D (RPM-3D), a medical technology company offering pre-operative planning and patient-specific guides designed to deliver surgical correction of deformities customized to the patient’s unique foot anatomy, for USD $20 million in an upfront cash payment, with...
Treace Medical Concepts signed an agreement to acquire certain assets of RedPoint Medical3D (RPM-3D), a medical technology company offering pre-operative planning and patient-specific guides designed to deliver surgical correction of deformities customized to the patient’s unique foot anatomy, for USD $20 million in an upfront cash payment, with up to $10 million in potential milestone payments.
Using patient CT scan data, RPM-3D applies software technologies to develop a three-dimensional pre-operative plan for correcting the patient’s deformity and produce a 3D-printed, patient-specific cut guide designed to efficiently make accurate, corrective cuts. RPM-3D software and systems will be integrated with Treace’s instrumentation and implant systems in 2023, with commercial introduction of patient-specific products expected in 2H24.
This announcement follows Treace Medical’s recently launched Adductoplasty Midfoot Correction System, SpeedRelease and TriTome Release Instruments, and S4A Anatomic Plating Kit; and its Micro-Lapiplasty Minimally Invasive System and SpeedPlate Rapid Compression Implant System, which are expected for full commercial release in late 2023.
John T. Treace, CEO, Founder and Board Member of Treace, said, “RPM-3D’s 22 patent applications further expand and reinforce our market-leading global IP portfolio covering technologies for the correction of bunion and related deformities. In addition, the RPM-3D purchase builds upon our acceleration in R&D initiatives that we announced in early 2022.”
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
